FUDAN FORWARD(SH:600624) Xin Lang Cai Jing·2025-09-30 01:51Core Viewpoint - ST Fuhua has faced significant challenges leading to a stock price drop and a halt in trading, primarily due to continuous losses, financial violations, and a decline in its pharmaceutical segment [2]. Group 1: Company Performance - As of the first half of 2025, ST Fuhua reported a net profit of -7.12 million and a non-recurring net profit of -11.64 million, indicating ongoing financial struggles [2]. - The pharmaceutical segment experienced a revenue decline of 7.57%, heavily impacted by centralized procurement policies, with Jiangsu Fuhua Pharmaceuticals incurring a loss of 13.48 million [2]. Group 2: Regulatory and Market Impact - The company disclosed violations in its annual reports from 2019 to 2023 on September 20, 2025, which severely damaged its reputation and investor trust [2]. - On September 23, 2025, the stock was designated as ST, reflecting the company's regulatory issues and operational problems, leading to increased downward pressure on the stock price [2]. Group 3: Market Sentiment and Technical Analysis - On September 25, 2025, a new "low-price" concept was introduced, but it did not lead to any substantial improvement in the company's fundamentals, making it difficult to boost the stock price [2]. - The stock was included in the "Dragon and Tiger List" on the same day, but given its ST status, this was likely a result of short-term speculative trading rather than a sustainable positive outlook [2]. - Recent negative events have raised investor concerns, leading to a potential outflow of funds, and there is caution regarding the upcoming quarterly report, which could further pressure the stock price if fund flows remain poor [2].